Literature DB >> 28417344

Biotherapy in Inflammatory Diseases of the CNS: Current Knowledge and Applications.

Nicolas Collongues1,2, Laure Michel3, Jérôme de Seze4,5.   

Abstract

OPINION STATEMENT: Biotherapy represents an innovative therapeutic approach that includes immunotherapy (vaccines, apheresis, and antibodies); gene therapy; and stem cell transplants. Their development helps to cross the bridge from bench to bedside and brings new hope of a cure for severe diseases in different fields of medicine. In neurology, a growing range of applications is being developed for these medications. Valuable results are now available in the field of autoimmunity, neuro-oncology, paraneoplastic manifestations, and neurodegenerative disorders. In this review, we examine the current and future applications of biotherapy in the field of inflammation of the central nervous system. We demonstrate its contribution in clinical practice, where it has enabled a significant level of effectiveness to be achieved. Indeed, the efficacy of these new biodrugs provides a solution for patients refractory to standard therapies, such as intravenous immunoglobulins in limbic encephalitis, plasma exchanges in neuromyelitis optica and anti-CD20 monoclonal antibodies in multiple sclerosis. They also mark the first steps towards individualized medicine.

Entities:  

Keywords:  Biotherapy; Gene therapy; Monoclonal antibody; Stem cell

Year:  2017        PMID: 28417344     DOI: 10.1007/s11940-017-0456-3

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  90 in total

1.  The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20.

Authors:  Jessica L Teeling; Wendy J M Mackus; Luus J J M Wiegman; Jeroen H N van den Brakel; Stephen A Beers; Ruth R French; Tom van Meerten; Saskia Ebeling; Tom Vink; Jerry W Slootstra; Paul W H I Parren; Martin J Glennie; Jan G J van de Winkel
Journal:  J Immunol       Date:  2006-07-01       Impact factor: 5.422

2.  Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study.

Authors:  Per S Sorensen; Steen Lisby; Richard Grove; Frederick Derosier; Steve Shackelford; Eva Havrdova; Jelena Drulovic; Massimo Filippi
Journal:  Neurology       Date:  2014-01-22       Impact factor: 9.910

3.  Postpartum Treatment With Immunoglobulin Does Not Prevent Relapses of Multiple Sclerosis in the Mother.

Authors:  Yara Dadalti Fragoso; Tarso Adoni; Soniza Vieira Alves-Leon; Nerio Dutra Azambuja; Amilton Antunes Barreira; Joseph Bruno Bidin Brooks; Denise Sisteroli Diniz Carneiro; Margarete J Carvalho; Rinaldo Claudino; Elizabeth Regina Comini-Frota; Renan Barros Domingues; Alessandro Finkelsztejn; Paulo Diniz Gama; Maria Cristina Brandao Giacomo; Sidney Gomes; Marcus Vinicius Magno Goncalves; Anderson Kuntz Grzesiuk; Damacio Ramon Kaimen-Maciel; Maria Fernanda Mendes; Nivea Macedo Oliveira Morales; Rogerio Rizo Morales; Andre Muniz; Regina Maria Papais-Alvarenga; Monica Koncke Fiuza Parolin; Sonia Beatriz Felix Ribeiro; Heloisa Helena Ruocco; Pedro Rippel Salgado; Fabio Siquineli; Doralina Brum Souza; Elza Dias Tosta; Claudia Cristina Ferreira Vasconcelos; Sandra Maria Garcia Almeida; Daniella Freire Ribeiro Bernardes; Simone Nascimento Castro; Rodrigo Assad Diniz Gama; Fabrizio Antonio Resende Gomide; Juliana Finkelzstejn; Josiane Lopes; Fabiani Honorato de Barros Lourenco; Gisele A Lourenco; Celso Luis Silva Oliveira; Francisco Tomaz Meneses Oliveira; Lucas Felix Oliveira; Cristiane Borges Patroclo; Wildea Lice de Carvalho Jennings Pereira; Juliana Safanelli; Alinne Martiniano Sahdo; Patricia Correa de Oliveira Saldanha; Yves Fumio Shinzato; Jorge Murilo Barbosa Souza; Denis Evandro Zani
Journal:  Health Care Women Int       Date:  2014-10-30

4.  Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study.

Authors:  Eduardo F Mysler; Alberto J Spindler; Renato Guzman; Marc Bijl; David Jayne; Richard A Furie; Frédéric A Houssiau; Jorn Drappa; David Close; Romeo Maciuca; Kajal Rao; Saba Shahdad; Paul Brunetta
Journal:  Arthritis Rheum       Date:  2013-09

5.  Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study.

Authors:  Eva Havrdova; Steven Galetta; Michael Hutchinson; Dusan Stefoski; David Bates; Chris H Polman; Paul W O'Connor; Gavin Giovannoni; J Theodore Phillips; Fred D Lublin; Amy Pace; Richard Kim; Robert Hyde
Journal:  Lancet Neurol       Date:  2009-02-07       Impact factor: 44.182

Review 6.  Concise review: combining human leukocyte antigen G and mesenchymal stem cells for immunosuppressant biotherapy.

Authors:  Abderrahim Naji; Nathalie Rouas-Freiss; Antoine Durrbach; Edgardo D Carosella; Luc Sensébé; Frédéric Deschaseaux
Journal:  Stem Cells       Date:  2013-11       Impact factor: 6.277

7.  Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial.

Authors:  Harold L Atkins; Marjorie Bowman; David Allan; Grizel Anstee; Douglas L Arnold; Amit Bar-Or; Isabelle Bence-Bruckler; Paul Birch; Christopher Bredeson; Jacqueline Chen; Dean Fergusson; Mike Halpenny; Linda Hamelin; Lothar Huebsch; Brian Hutton; Pierre Laneuville; Yves Lapierre; Hyunwoo Lee; Lisa Martin; Sheryl McDiarmid; Paul O'Connor; Timothy Ramsay; Mitchell Sabloff; Lisa Walker; Mark S Freedman
Journal:  Lancet       Date:  2016-06-09       Impact factor: 79.321

Review 8.  Monoclonal antibodies in neuro-oncology: Getting past the blood-brain barrier.

Authors:  Lois A Lampson
Journal:  MAbs       Date:  2011-03-01       Impact factor: 5.857

Review 9.  Targeted therapeutics in SLE: emerging strategies to modulate the interferon pathway.

Authors:  Shereen Oon; Nicholas J Wilson; Ian Wicks
Journal:  Clin Transl Immunology       Date:  2016-05-13

Review 10.  Update on Biologic Therapies for Systemic Lupus Erythematosus.

Authors:  Helena Hiemisch Lobo Borba; Andreas Funke; Astrid Wiens; Shirley Ramos da Rosa Utiyama; Cássio Marques Perlin; Roberto Pontarolo
Journal:  Curr Rheumatol Rep       Date:  2016-07       Impact factor: 4.686

View more
  1 in total

1.  Phosphorylation of ERK-Dependent NF-κB Triggers NLRP3 Inflammasome Mediated by Vimentin in EV71-Infected Glioblastoma Cells.

Authors:  Zelong Gong; Xuefeng Gao; Qingqing Yang; Jingxian Lun; Hansen Xiao; Jiayu Zhong; Hong Cao
Journal:  Molecules       Date:  2022-06-29       Impact factor: 4.927

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.